-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Q1 2026 revenue fell 5.5% reported to EUR4,612M, in line with consensus, though organic growth remained positive at 3.9% (Q4: +8.2%). Operating margin (excluding special items) improved to 10.1% from 9.4% prior year, supported by FME25+ savings of EUR50M, while reported operating income declined 14% due to EUR181M in transformation costs. Care Delivery posted strongest performance with organic revenue +6.1% and margin up 1.8%-pts to 12.1%, benefiting from TDAPA reimbursement tailwinds, though U.S. same market treatment continued declining (-0.4%). FME reaffirmed its 2026 guidance for broadly flat revenue and operating income at constant currencies, expecting stronger 1H 2026 before TDAPA benefits phase out in 2H. While we are positive on sustained FME25+ cost savings, the timeline for U.S. same market volume recovery remains uncertain, which we see as a key concern. FME expects flat U.S. treatment growth in 2026 but provided no specific recovery timeline, suggesting elevated uncertainty remains, in our view.